Not Yet RecruitingNot Applicable

Assessment of a New Traction Device in Submucosal Dissection of Colorectal Lesions

France30 participantsStarted 2025-12-15

Plain-language summary

Colorectal cancer is a major public health issue. In France, in 2015, there were 40,000 new cases and 17,000 deaths. It develops from adenomas or scalloped polyps, which are usually accessible for endoscopic resection. Piece-meal mucosectomy is the standard technique in Europe and the USA for lesions larger than 2 cm. It has certain advantages, such as its ease of learning, low morbidity and speed of execution. However, it has one major disadvantage, namely the low rate of monobloc resection and R0 for lesions larger than 2 cm. Submucosal dissection (SMD) has become the standard technique for endoscopic resection of superficial colorectal lesions larger than 2 cm, particularly if the lesion presents a risk of superficial degeneration. Unlike mucosectomy, this technique allows for monobloc resection targeting R0 for all types of superficial lesions without size limitations, enabling histological analysis without data loss and with a recurrence rate of less than 2%. However, there are numerous disadvantages to dissection: * SMD is more difficult than mucosectomy, with a long learning curve, limiting its use to expert centres. * The morbidity of dissection is higher than that of mucosectomy, with a risk of perforation of 4% vs. 1%. * The procedure takes on average three times longer than mucosectomy. From a technical standpoint, various methods have been described to facilitate the procedure, in particular traction using clips and elastic bands, which is the most widely used method in France. Micro-Tech offers a new traction device, SureTrac, which is designed to perform single or multi-polar traction and to adjust the intensity of traction during dissection. The product is CE marked but has not yet been distributed in France. No data are currently available in the literature on this product other than a case report submitted for publication. A pilot study conducted by an expert centre is therefore necessary. This is why this study is being initiated.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient, male or female, aged ≥ 18 years old * Patient with a colorectal lesion larger than 2 cm * Patient eligible for SMD with elastic traction * Patient affiliated with or beneficiary of a social security scheme * French-speaking patient who has signed an informed consent form Exclusion Criteria: * Patients in poor general health who should not undergo endoscopy. * Patients with an upper digestive tract that cannot be accessed by the endoscope. * Patients with severe coagulation disorders and diseases associated with a risk of haemorrhage (platelets \<50G/L, PT \< 50%, INR \> 1.5, APTT \>1.5). * Patients who are allergic to the instrument and to the drugs administered during the operation * Patients who are not compatible with the use of the product according to the diagnosis Patients with lesions located in the appendix, ileocecal valve or within a diverticulum * Patients with lesions that present a risk of deep submucosal invasion based on their morphological appearance (Kudo lesion \> 10 mm or Sano IIIB \> 10 mm or connect III) * Patients with recurrence of a lesion previously resected by endoscopy or surgery * Patients with a history of chronic inflammatory bowel disease (IBD) or familial adenomatous polyposis (FAP) * Patients with a history of pelvic radiotherapy * Patients for whom follow-up data cannot be collected * Pregnant women * Protected patients: adults under guardianship, curatorship or other legal protection, deprived of their liber…

What they're measuring

Submucosal dissection feasibility with the SureTrac traction device.

Timeframe: Day 0 (resection day)

Trial details

NCT IDNCT07263997

SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01-15

Contact for this trial

Sarah LEBLANC, MD

+ 33 6 22 22 20 64 sarahleblanc34@hotmail.com